Novartis-Alnylam deal produces revenue for Isis

09/13/2005 | Yahoo!

The recently announced Novartis partnership with Alnylam for the development of RNA interference drugs is expected to produce nearly $4 million for California-based Isis Pharmaceuticals. Isis said it is entitled to a share of the Novartis upfront payments to Alnylam as a result of the technology Isis had licensed to Alnylam.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Pompano Beach, FL